Charité - Universitätsmedizin Berlin

Hospital


Location: Berlin, Germany (DE) DE

ISNI: 0000000122184662

ROR: https://ror.org/001w7jn25

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies (2022) Haegele M, Mueller KR, Denkert C, Schneeweiss A, Sinn BV, Untch M, Van Mackelenbergh MT, et al. Conference contribution When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study (2022) Hampl M, Jaeger A, Eulenburg C, Prieske K, Hambrecht J, Fuerst S, Klapdor R, et al. Conference contribution A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST) (2022) Ahrens M, Escudier B, Haanen J, Gross-Goupil M, Boleti E, Gravis G, Grimm MO, et al. Conference contribution Factors associated with long-term survival after failure a chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphomas:a role for allogeneic stem cell transplantation? (2022) Derigs P, Bethge W, Holtick U, Von Tresckow B, Ayuk F, Penack O, Vucinic V, et al. Conference contribution Prophylaxis of bacterial Infections and Pneumocystis jirovecii pneumonia in Female Patients with hematological and oncological Diseases: Updated Guideline of the Working Group on Infections (AGIHO) of the German Society for Hematology and Oncology (DGHO) (2022) Classen AY, Henze L, Von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Duran GL, Alakel N, et al. Conference contribution Auswirkungen eines verkurzten Dosierungsintervalls von Lanreotid-Autogel (LAN) auf die Tumorwachstumsrate ( TGR) bei Patienten mit fortgeschrittenen Neuroendokrinen Tumoren (NETs) in der prospektiven, einarmigen, Phase 2 Studie CLARINET FORTE (2022) Pape UF, Dromain C, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Capdevilla J, et al. Conference contribution 12-month trends in health-related quality of life after hospitalization - comparison of tumor entities (2022) Eichler M, Hornemann B, Hoenig K, Bergelt C, Faller H, Maatouk , Stein B, et al. Conference contribution Immunophenotypes and Targets of clonally expanded T Cells in the Bone Marrow of Patients with acquired Aplastic Anemia (2022) Ben Hamza A, Welters C, Bruggemann M, Dietze K, Bullinger L, Brummendorf TH, Winkler T, et al. Conference contribution The CAR-HAMATOTOX for risk stratification of severe infections and for the adjustment of antibacterial prophylaxis prior to CD19-targeted CAR T-cell therapy (2022) Rejeski K, Perez A, Iacoboni G, Penack O, Buecklein , Mougiakakos D, Blumenberg , et al. Conference contribution Real-world data in children with achondroplasia after licensing of Vosoritide (2022) Palm K, Bechthold-Dalla Pozza S, Gausche R, Hoegler W, Hoyer-Kuhn H, Huebner A, Keller A, et al. Conference contribution